Cargando…

How Well Does the Target INR Level Maintain in Warfarin-Treated Patients with Non-ValvularAtrial Fibrillation?

PURPOSE: Although warfarin is an effective oral anticoagulation (OAC) drug to reduce the risk of thromboembolism in patients with non-valvular atrial fibrillation (NVAF), long term follow-up data are scarce to be certain whether the target INR level is maintained in warfarin-treated patients in Kore...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jun Hyung, Song, Young Bin, Shin, Dae Hee, Kim, Je Sang, Choi, Jin-Oh, On, Young Kun, Kim, June Soo
Formato:	Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2009
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2649856/ https://www.ncbi.nlm.nih.gov/pubmed/19259353 http://dx.doi.org/10.3349/ymj.2009.50.1.83

Ejemplares similares

Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
por: Nelson, Winnie W., et al.
Publicado: (2014)

Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin
por: Luengsupabul, Sirote, et al.
Publicado: (2020)

The comparison of non-vitamin K antagonist oral anticoagulants versus well-managed warfarin with a lower INR target of 1.5 to 2.5 in Asians patients with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2019)

Risk of major bleeding at different PT-INR ranges in elderly Japanese patients with non-valvular atrial fibrillation receiving warfarin: a nested case-control study
por: Ohgushi, Atsushi, et al.
Publicado: (2016)

Predictors for INR-control in a well-managed warfarin treatment setting
por: Björck, Fredrik, et al.
Publicado: (2018)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT)
por: Smith, Danielle E, et al.
Publicado: (2010)

Is Lighter Intensity of Warfarin Therapy Enough for Korean Patients with Non-Valvular Atrial Fibrillation?
por: Lee, So-Ryoung
Publicado: (2019)

Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation
por: Wang, Li, et al.
Publicado: (2013)

Quality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KORean Atrial Fibrillation Investigation II
por: Oh, Seil, et al.
Publicado: (2018)

A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation
por: Pengo, Vittorio, et al.
Publicado: (2015)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure
por: Martinez, Brandon K., et al.
Publicado: (2018)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
por: Birkinshaw, Alexander, et al.
Publicado: (2020)

Impact of age on thromboembolic events in patients with non‐valvular atrial fibrillation
por: Kim, Yun Gi, et al.
Publicado: (2019)

Comparison of Prolonged Atrial Electromechanical Delays with Different Definitions in the Discrimination of Patients with Non-Valvular Paroxysmal Atrial Fibrillation
por: Lee, Dong Hyun, et al.
Publicado: (2015)

Does prophylactic antibiotic administration for tooth extraction affect PT-INR in patients taking warfarin?
por: Iwata, Eiji, et al.
Publicado: (2020)

Impact of serum albumin levels on supratherapeutic PT-INR control and bleeding risk in atrial fibrillation patients on warfarin: A prospective cohort study
por: Kawai, Mayumi, et al.
Publicado: (2019)

Warfarin/herbal drink interaction: Elevated INR: case report
Publicado: (2021)

A CONTROVERSY: WARFARIN FAILURE IN COVID-19 WITH SUPRATHERAPEUTIC INR
por: Ur Rahman, Saad
Publicado: (2023)

Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with Valvular heart diseases: a meta-analysis
por: He, Qiyu, et al.
Publicado: (2019)

Anticoagulation Control with Acenocoumarol or Warfarin in Non-Valvular Atrial Fibrillation in Primary Care (Fantas-TIC Study)
por: Dalmau Llorca, M. Rosa, et al.
Publicado: (2021)

Metabolomic and Proteomic Analyses of Persistent Valvular Atrial Fibrillation and Non-Valvular Atrial Fibrillation
por: Hu, Bo, et al.
Publicado: (2021)

Optimal INR level in elderly and non-elderly patients with atrial fibrillation receiving warfarin: a report from the COOL-AF nationwide registry in Thailand
por: Krittayaphong, Rungroj, et al.
Publicado: (2020)

Chinese stroke patients with atrial fibrillation used Robert's age-adjusted warfarin loading protocol obtained good INR results within therapeutic range
por: Luo, Weiliang, et al.
Publicado: (2023)

Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study
por: Bo, Simona, et al.
Publicado: (2007)

Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease
por: Briasoulis, Alexandros, et al.
Publicado: (2018)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
por: Kjerpeseth, Lars J., et al.
Publicado: (2019)

Comparison of dabigatran and warfarin used in patients with non-valvular atrial fibrillation: Meta-analysis of random control trial
por: Yu, Yi-bo, et al.
Publicado: (2018)

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
por: Li, Wei-Jia, et al.
Publicado: (2021)

Efficacy and safety of warfarin in patients with non-valvular atrial fibrillation and CKD G3–G5D
por: Welander, Frida, et al.
Publicado: (2022)

Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation
por: Hwang, Ki Won, et al.
Publicado: (2023)

Recommended Therapeutic INR Range for Patients with Antiphospholipid Syndrome on Warfarin Anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for Reducing Risk of Recurrent Thromboembolic Events?
por: Kim, Esther, et al.
Publicado: (2016)

Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
por: Coleman, Craig I., et al.
Publicado: (2016)

Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis
por: de Souza Lima Bitar, Yasmin, et al.
Publicado: (2019)

Association between direct-acting oral anticoagulants vs. warfarin with the risk of osteoporosis in patients with non-valvular atrial fibrillation
por: Akhtar, Tauseef, et al.
Publicado: (2020)

A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk
por: Liu, Peng-Hui, et al.
Publicado: (2022)

Comparison of the Efficacy and Safety of Apixaban and Warfarin in the Prevention of Stroke in Patients With Non-valvular Atrial Fibrillation: A Meta-Analysis
por: Memon, Rahat A, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e9173jeu4ball5i8gp2b1reup5